For treatment of latent tuberculosis infection (LTBI), short-course rifamycin-based regimens are preferred over longer-course isoniazid monotherapy, according to guidelines published in the Feb. 14 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Treatment Action Group releases an updated version of its Activist’s Guide to the LAM Test with a complementary resource that tracks the status of LAM uptake in the 30 high TB/HIV burden countries.

The Stop TB Partnership is currently recruiting for a TB Prevalence Survey Coordinator who will be based in Gaborone, Botswana.

The Global TB Caucus is looking for a Regional Coordinator to support the work carried out in the Africa region. The position is open to individuals who meet the required criteria and reside in the Africa region.

Aidspan: Global Fund Observer

New research has shed light on how mycobacteria grow. This discovery could explain why some members of this family of single-celled organisms, which includes the bacillus that causes tuberculosis, can develop resistance to antibiotics.

Treatment with 4 months of rifampin (4R) for latent tuberculosis (TB) infection was associated with substantially higher adherence, lower costs, and lower risk for severe hepatoxicity compared with 9 months of isoniazid (9H), according to study results published in the European Respiratory Journal.

In September 2018, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, issued its Strategic Plan for Tuberculosis Research, which outlined research priorities to reduce and ultimately end the burden of tuberculosis (TB). TB is a bacterial disease that has claimed the lives of more than a billion people in the past two centuries. Now, a new “Perspective” in The Journal of Infectious Diseases by NIAID Director Anthony S. Fauci, M.D., and other Institute officials summarizes recent progress in improved TB diagnostics, therapeutic regimens and prevention approaches that made 2019 a “banner year” for TB research.

In patients without a contraindication, rifampicin may be the safest treatment option for latent tuberculosis (TB) infection, according to results of a study published in the Lancet Infectious Diseases.